Flt3 ligand level reflects hematopoietic progenitor cell function in aplastic anemia and chemotherapy-induced bone marrow aplasia.

Flt3 ligand (flt3L) is a member of a small family of cytokines acting as tyrosine kinase receptor ligands that stimulate the proliferation of primitive hematopoietic progenitors in vitro. To gain insight into the physiological role of flt3L in early hematopoiesis, levels of flt3L were determined in serum of patients with multilineage bone marrow failure and related to the severity of stem cell depletion. In patients with aplastic anemia (AA) and in cancer patients with chemotherapy-induced transient suppression of hematopoiesis, flt3L fluctuated in an inverse relationship to the degree of bone marrow failure. In severe AA at diagnosis, levels of circulating soluble flt3L were highly elevated (2,653 +/- 353 pg/mL) as compared with normal blood serum values of 14 +/- 39 pg/mL. Flt3L returned to near normal levels within the first 3 months following successful bone marrow transplantation and in autologous remission induced by immunosuppressive therapy with antilymphocyte globulin (ALG; 100 +/- 31 and 183 +/- 14 pg/mL, respectively). In contrast, rejection of the graft or relapse of the disease after ALG was accompanied by an increase to high pretreatment concentrations of the circulating cytokine (3,770 +/- 2,485 and 1,788 +/- 233 pg/mL, respectively). Flt3L in serum inversely correlated with the colony-forming ability of AA bone marrow precursors in vitro (R = -.86), indicating that the concentration of the ligand reflects hematopoiesis at the progenitor cell level. Flt3L increased to 2,500 pg/mL in the serum of leukemia patients during chemoradiotherapy-induced bone marrow suppression and returned to normal values along with hematopoietic recovery. Expression of the membrane-bound form of flt3L was significantly elevated in mononuclear bone marrow and peripheral blood cells from patients with severe pancytopenia, suggesting de novo synthesis of the factor in response to bone marrow failure. The data provide a strong argument for the involvement of flt3L in the regulation of early hematopoiesis in vivo.

[1]  K. Kaushansky.  Thrombopoietin the primary regulator of platelet production. , 1995, Trends in endocrinology and metabolism: TEM.

[2]  C. Nissen,et al.  Deficiency of CD34+c‐kit+ and CD34+38‐ hematopoietic precursors in aplastic anemia after immunosuppressive treatment , 1996, American journal of hematology.

[3]  N. Young,et al.  Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. , 1996, Blood.

[4]  H. Hume,et al.  Stem cell factor serum levels may not be clinically relevant [letter] , 1996 .

[5]  H. Hume,et al.  Stem cell factor serum levels may not be clinically relevant. , 1996, Blood.

[6]  J. Prchal,et al.  Plasma/serum levels of flt3 ligand are low in normal individuals and highly elevated in patients with Fanconi anemia and acquired aplastic anemia. , 1995, Blood.

[7]  David A. Williams,et al.  Effect of flt3 ligand on the ex vivo expansion of human CD34+ hematopoietic progenitor cells. , 1995, Blood.

[8]  A. Tichelli,et al.  Persistent growth impairment of bone marrow stroma after antilymphocyte globulin treatment for severe aplastic anaemia and its association with relapse , 1995, European journal of haematology.

[9]  H. Broxmeyer,et al.  Flt3 ligand stimulates/costimulates the growth of myeloid stem/progenitor cells. , 1995, Experimental hematology.

[10]  S. Heimfeld,et al.  Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. , 1995, The New England journal of medicine.

[11]  S. Goff,et al.  Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. , 1995, Immunity.

[12]  N. Young,et al.  The treatment of severe acquired aplastic anemia. , 1995, Blood.

[13]  C. Hannum,et al.  FLT3/FLK2 ligand promotes the growth of murine stem cells and the expansion of colony-forming cells and spleen colony-forming units. , 1995, Blood.

[14]  R. Kastelein,et al.  FLK-2/FLT-3 ligand regulates the growth of early myeloid progenitors isolated from human fetal liver. , 1995, Blood.

[15]  N. Copeland,et al.  Identification of soluble and membrane-bound isoforms of the murine flt3 ligand generated by alternative splicing of mRNAs. , 1995, Oncogene.

[16]  Carroll,et al.  Cellular and molecular characterization of the role of the flk-2/flt-3 receptor tyrosine kinase in hematopoietic stem cells. , 1994, Blood.

[17]  H. Heimpel,et al.  Serum erythropotietin and serum transferrin receptor levels in aplastic anaemia , 1994, British journal of haematology.

[18]  N. Young,et al.  Phenotypic and functional analysis of bone marrow progenitor cell compartment in bone marrow failure , 1994, British journal of haematology.

[19]  H. Mckenna,et al.  Cloning of the human homologue of the murine flt3 ligand: a growth factor for early hematopoietic progenitor cells. , 1994, Blood.

[20]  T. Mcclanahan,et al.  Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs , 1994, Nature.

[21]  M. Goldberg,et al.  Physiology of erythropoietin production. , 1994, Seminars in hematology.

[22]  M. Ratajczak,et al.  STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[23]  T. Farrah,et al.  Molecular cloning of a ligand for the flt3 flk-2 tyrosine kinase receptor: A proliferative factor for primitive hematopoietic cells , 1993, Cell.

[24]  R. Fleischman.  From white spots to stem cells: the role of the Kit receptor in mammalian development. , 1993, Trends in genetics : TIG.

[25]  A. Gratwohl,et al.  Levels of soluble stem cell factor in serum of patients with aplastic anemia. , 1993, Blood.

[26]  D. Chang,et al.  Soluble stem cell factor in human serum. , 1993, Blood.

[27]  C. Nissen.  [The pathophysiology of aplastic anemia]. , 1991, Gematologiia i transfuziologiia.

[28]  K. Zsebo,et al.  Stem cell factor stimulates the in vitro growth of bone marrow cells from aplastic anemia patients. , 1992, Blood.

[29]  D. Birnbaum,et al.  Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family. , 1991, Oncogene.

[30]  D. Pardoll,et al.  A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations , 1991, Cell.

[31]  A. Gratwohl,et al.  Management of aplastic anemia , 1991, European journal of haematology.

[32]  L. Moretta,et al.  Immune suppression of hematopoiesis in aplastic anemia: activity of T-gamma lymphocytes. , 1980, Journal of immunology.

[33]  R Revol Núñez,et al.  [Aplastic anemia]. , 1970, Archivos Argentinos de Pediatria.